NanoSyrinx, a synthetic biotech firm, secured £10 million in funding to propel its pioneering nano syringes platform. This technology enables targeted intracellular delivery of biologic therapeutics. The financing round saw contributions from BGF, Octopus Ventures, M Ventures, and Eli Lilly and Company. The company aims to enhance its technology to address previously undruggable intracellular targets, potentially revolutionizing the field of biologic therapies.
Last year, NanoSyrinx received seed funding which allowed initial development of its nano syringes technology. The company demonstrated proof of concept by delivering functional gene editors directly to specific cells. In contrast, the recent £10 million funding will significantly scale their operations and expedite the development of new therapeutics. Previous funding rounds did not have the high-profile participation of global pharmaceutical companies like Eli Lilly and Company, highlighting increased confidence in NanoSyrinx’s potential.
Moreover, NanoSyrinx’s earlier endeavors were focused more on research and development without substantial industrial collaboration. The latest investment round indicates a strategic shift towards commercialization and broader industry partnerships. This progression underscores the growing recognition of intracellular delivery methods as critical to advancing biologic therapies.
Technology Advancement and Applications
The proprietary technology of NanoSyrinx revolves around naturally occurring nano syringes. These nano-scale devices can selectively deliver peptides, proteins, and functional gene editors directly into the cytosol of target cells. This approach could unlock new therapeutic options for diseases previously deemed untreatable due to intracellular barriers. The additional funds will further develop this technology, aiming to bring innovative treatments to market swiftly.
Leadership and Strategic Direction
In addition to the funding announcement, NanoSyrinx appointed Dr. Edwin Moses as the Chairman of the Board. Dr. Moses brings over three decades of experience in the life sciences sector, having served on the boards of more than 20 companies. His expertise is expected to guide NanoSyrinx through its next growth phase. Dr. Moses expressed his enthusiasm for the company’s potential, emphasizing the unique impact of the nano syringes platform on therapeutic delivery.
NanoSyrinx’s technology promises to make a tremendous positive difference to the very challenging problem of intracellular delivery of therapeutics. I am delighted to join the Board and help build on the momentum of this latest fundraiser to support the Company and its leadership team in further developing this unique platform, which has the potential to create enormous value and make a real difference to patients’ lives.
The fundraising round was co-led by BGF, Octopus Ventures, and M Ventures, with participation from existing investors IQ Capital and Meltwind. Their involvement underscores the growing investor interest in NanoSyrinx’s potential to revolutionize therapeutic delivery systems. Lucy Edwardes Jones from BGF highlighted the importance of overcoming delivery challenges in biologic therapies, which NanoSyrinx’s technology addresses.
“While huge advances have been made in the field of biologic therapies, the delivery challenge remains a key bottleneck. We are excited by the potential of NanoSyrinx’s unique technology to unlock this, enabling promising new drugs to reach previously inaccessible disease targets in the body.”
The inclusion of a globally recognized pharmaceutical firm like Eli Lilly and Company marks a milestone for NanoSyrinx. This collaboration could potentially expedite the clinical application of their technology and facilitate access to a broader market. Eli Lilly’s involvement not only provides financial backing but also industry expertise and validation of NanoSyrinx’s innovative approach.
The advancement of NanoSyrinx’s technology platform signifies a pivotal development in the field of biologic therapeutics. The company’s focus on addressing intracellular targets could lead to groundbreaking treatments for complex diseases. Investors and industry leaders alike are showing heightened interest, recognizing the platform’s potential to transform therapeutic delivery. As NanoSyrinx progresses, its innovative approach to intracellular delivery could set new standards in biotechnology and medicine.
